metabolic	B:C1328813
profiling	I:C1328813
of	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
and	O
mild	O
cognitive	I:C1270972
impairment	I:C1270972
Early	O
diagnosis	I:C0596473
of	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
and	O
mild	O
cognitive	I:C1270972
impairment	I:C1270972
is	O
important	O
to	O
enable	O
prompt	O
treatment	O
and	O
improve	O
patient	I:C0243095
welfare	I:C0243095
,	O
yet	O
no	O
standard	O
diagnostic	I:C0086143
test	I:C0086143
is	O
available	O
.	O

metabolic	O
profiling	I:C1328813
of	O
Parkinson	B:C0030567
's	I:C0030567
disease	I:C0030567
and	O
mild	O
cognitive	I:C1270972
impairment	I:C1270972
Early	O
diagnosis	I:C0596473
of	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
and	O
mild	O
cognitive	I:C1270972
impairment	I:C1270972
is	O
important	O
to	O
enable	O
prompt	O
treatment	O
and	O
improve	O
patient	I:C0243095
welfare	I:C0243095
,	O
yet	O
no	O
standard	O
diagnostic	I:C0086143
test	I:C0086143
is	O
available	O
.	O

metabolic	O
profiling	I:C1328813
of	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
and	O
mild	B:C1270972
cognitive	I:C1270972
impairment	I:C1270972
Early	O
diagnosis	I:C0596473
of	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
and	O
mild	O
cognitive	I:C1270972
impairment	I:C1270972
is	O
important	O
to	O
enable	O
prompt	O
treatment	O
and	O
improve	O
patient	I:C0243095
welfare	I:C0243095
,	O
yet	O
no	O
standard	O
diagnostic	I:C0086143
test	I:C0086143
is	O
available	O
.	O

metabolic	O
profiling	I:C1328813
of	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
and	O
mild	O
cognitive	I:C1270972
impairment	I:C1270972
Early	B:C0596473
diagnosis	I:C0596473
of	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
and	O
mild	O
cognitive	I:C1270972
impairment	I:C1270972
is	O
important	O
to	O
enable	O
prompt	O
treatment	O
and	O
improve	O
patient	I:C0243095
welfare	I:C0243095
,	O
yet	O
no	O
standard	O
diagnostic	I:C0086143
test	I:C0086143
is	O
available	O
.	O

metabolic	O
profiling	I:C1328813
of	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
and	O
mild	O
cognitive	I:C1270972
impairment	I:C1270972
Early	O
diagnosis	I:C0596473
of	O
Parkinson	B:C0030567
's	I:C0030567
disease	I:C0030567
and	O
mild	O
cognitive	I:C1270972
impairment	I:C1270972
is	O
important	O
to	O
enable	O
prompt	O
treatment	O
and	O
improve	O
patient	I:C0243095
welfare	I:C0243095
,	O
yet	O
no	O
standard	O
diagnostic	I:C0086143
test	I:C0086143
is	O
available	O
.	O

metabolic	O
profiling	I:C1328813
of	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
and	O
mild	O
cognitive	I:C1270972
impairment	I:C1270972
Early	O
diagnosis	I:C0596473
of	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
and	O
mild	B:C1270972
cognitive	I:C1270972
impairment	I:C1270972
is	O
important	O
to	O
enable	O
prompt	O
treatment	O
and	O
improve	O
patient	I:C0243095
welfare	I:C0243095
,	O
yet	O
no	O
standard	O
diagnostic	I:C0086143
test	I:C0086143
is	O
available	O
.	O

metabolic	O
profiling	I:C1328813
of	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
and	O
mild	O
cognitive	I:C1270972
impairment	I:C1270972
Early	O
diagnosis	I:C0596473
of	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
and	O
mild	O
cognitive	I:C1270972
impairment	I:C1270972
is	O
important	O
to	O
enable	O
prompt	O
treatment	O
and	O
improve	B:C0243095
patient	I:C0243095
welfare	I:C0243095
,	O
yet	O
no	O
standard	O
diagnostic	I:C0086143
test	I:C0086143
is	O
available	O
.	O

metabolic	O
profiling	I:C1328813
of	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
and	O
mild	O
cognitive	I:C1270972
impairment	I:C1270972
Early	O
diagnosis	I:C0596473
of	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
and	O
mild	O
cognitive	I:C1270972
impairment	I:C1270972
is	O
important	O
to	O
enable	O
prompt	O
treatment	O
and	O
improve	O
patient	I:C0243095
welfare	I:C0243095
,	O
yet	O
no	O
standard	B:C0086143
diagnostic	I:C0086143
test	I:C0086143
is	O
available	O
.	O

Metabolomics	B:C1328813
is	O
a	O
powerful	O
tool	O
used	O
to	O
elucidate	O
disease	I:C1515006
mechanisms	I:C1515006
and	O
identify	O
potential	O
biomarkers	I:C0005516
.	O

Metabolomics	O
is	O
a	O
powerful	O
tool	O
used	O
to	O
elucidate	B:C1515006
disease	I:C1515006
mechanisms	I:C1515006
and	O
identify	O
potential	O
biomarkers	I:C0005516
.	O

Metabolomics	O
is	O
a	O
powerful	O
tool	O
used	O
to	O
elucidate	O
disease	I:C1515006
mechanisms	I:C1515006
and	O
identify	O
potential	B:C0005516
biomarkers	I:C0005516
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
use	O
metabolic	B:C1328813
profiling	I:C1328813
to	O
understand	O
the	O
pathoetiology	O
of	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
and	O
to	O
identify	O
potential	O
disease	I:C0005516
biomarkers	I:C0005516
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
use	O
metabolic	O
profiling	I:C1328813
to	O
understand	O
the	O
pathoetiology	O
of	O
Parkinson	B:C0030567
's	I:C0030567
disease	I:C0030567
and	O
to	O
identify	O
potential	O
disease	I:C0005516
biomarkers	I:C0005516
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
use	O
metabolic	O
profiling	I:C1328813
to	O
understand	O
the	O
pathoetiology	O
of	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
and	O
to	O
identify	O
potential	B:C0005516
disease	I:C0005516
biomarkers	I:C0005516
.	O

This	O
study	O
compared	O
the	O
serological	O
metabolomic	B:C1328813
profiles	I:C1328813
of	O
early	O
-	O
stage	O
Parkinson	O
's	I:C0030567
patients	O
(	O
diagnosed	O
<	O
12	O
months	O
)	O
to	O
asymptomatic	O
matched	I:C0231221
controls	I:C0231221
using	O
an	O
established	O
array	O
based	O
detection	O
system	O
(	O
DiscoveryHD4	O
™	O
,	O
Metabolon	O
,	O
UK	O
)	O
,	O
correlating	O
metabolite	I:C0243095
levels	I:C0243095
to	O
clinical	O
measurements	O
of	O
cognitive	O
impairment	I:C0338656
.	O

This	O
study	O
compared	O
the	O
serological	O
metabolomic	O
profiles	I:C1328813
of	O
early	O
-	O
stage	O
Parkinson	B:C0030567
's	I:C0030567
patients	O
(	O
diagnosed	O
<	O
12	O
months	O
)	O
to	O
asymptomatic	O
matched	I:C0231221
controls	I:C0231221
using	O
an	O
established	O
array	O
based	O
detection	O
system	O
(	O
DiscoveryHD4	O
™	O
,	O
Metabolon	O
,	O
UK	O
)	O
,	O
correlating	O
metabolite	I:C0243095
levels	I:C0243095
to	O
clinical	O
measurements	O
of	O
cognitive	O
impairment	I:C0338656
.	O

This	O
study	O
compared	O
the	O
serological	O
metabolomic	O
profiles	I:C1328813
of	O
early	O
-	O
stage	O
Parkinson	O
's	I:C0030567
patients	O
(	O
diagnosed	B:C0011900
<	O
12	O
months	O
)	O
to	O
asymptomatic	O
matched	I:C0231221
controls	I:C0231221
using	O
an	O
established	O
array	O
based	O
detection	O
system	O
(	O
DiscoveryHD4	O
™	O
,	O
Metabolon	O
,	O
UK	O
)	O
,	O
correlating	O
metabolite	I:C0243095
levels	I:C0243095
to	O
clinical	O
measurements	O
of	O
cognitive	O
impairment	I:C0338656
.	O

This	O
study	O
compared	O
the	O
serological	O
metabolomic	O
profiles	I:C1328813
of	O
early	O
-	O
stage	O
Parkinson	O
's	I:C0030567
patients	O
(	O
diagnosed	O
<	O
12	O
months	O
)	O
to	O
asymptomatic	B:C0231221
matched	I:C0231221
controls	I:C0231221
using	O
an	O
established	O
array	O
based	O
detection	O
system	O
(	O
DiscoveryHD4	O
™	O
,	O
Metabolon	O
,	O
UK	O
)	O
,	O
correlating	O
metabolite	I:C0243095
levels	I:C0243095
to	O
clinical	O
measurements	O
of	O
cognitive	O
impairment	I:C0338656
.	O

This	O
study	O
compared	O
the	O
serological	O
metabolomic	O
profiles	I:C1328813
of	O
early	O
-	O
stage	O
Parkinson	O
's	I:C0030567
patients	O
(	O
diagnosed	O
<	O
12	O
months	O
)	O
to	O
asymptomatic	O
matched	I:C0231221
controls	I:C0231221
using	O
an	O
established	O
array	O
based	O
detection	O
system	O
(	O
DiscoveryHD4	O
™	O
,	O
Metabolon	O
,	O
UK	B:C0041700
)	O
,	O
correlating	O
metabolite	I:C0243095
levels	I:C0243095
to	O
clinical	O
measurements	O
of	O
cognitive	O
impairment	I:C0338656
.	O

This	O
study	O
compared	O
the	O
serological	O
metabolomic	O
profiles	I:C1328813
of	O
early	O
-	O
stage	O
Parkinson	O
's	I:C0030567
patients	O
(	O
diagnosed	O
<	O
12	O
months	O
)	O
to	O
asymptomatic	O
matched	I:C0231221
controls	I:C0231221
using	O
an	O
established	O
array	O
based	O
detection	O
system	O
(	O
DiscoveryHD4	O
™	O
,	O
Metabolon	O
,	O
UK	O
)	O
,	O
correlating	B:C0243095
metabolite	I:C0243095
levels	I:C0243095
to	O
clinical	O
measurements	O
of	O
cognitive	O
impairment	I:C0338656
.	O

This	O
study	O
compared	O
the	O
serological	O
metabolomic	O
profiles	I:C1328813
of	O
early	O
-	O
stage	O
Parkinson	O
's	I:C0030567
patients	O
(	O
diagnosed	O
<	O
12	O
months	O
)	O
to	O
asymptomatic	O
matched	I:C0231221
controls	I:C0231221
using	O
an	O
established	O
array	O
based	O
detection	O
system	O
(	O
DiscoveryHD4	O
™	O
,	O
Metabolon	O
,	O
UK	O
)	O
,	O
correlating	O
metabolite	I:C0243095
levels	I:C0243095
to	O
clinical	O
measurements	O
of	O
cognitive	B:C0338656
impairment	I:C0338656
.	O

A	O
total	O
of	O
1434	O
serological	O
metabolites	B:C0870883
were	O
assessed	O
in	O
early	O
-	O
stage	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
cases	O
(	O
n	O
=	O
41	O
)	O
and	O
asymptomatic	O
matched	I:C0231221
controls	I:C0231221
(	O
n	O
=	O
40	O
)	O
.	O

A	O
total	O
of	O
1434	O
serological	O
metabolites	O
were	O
assessed	O
in	O
early	O
-	O
stage	O
Parkinson	B:C0030567
's	I:C0030567
disease	I:C0030567
cases	O
(	O
n	O
=	O
41	O
)	O
and	O
asymptomatic	O
matched	I:C0231221
controls	I:C0231221
(	O
n	O
=	O
40	O
)	O
.	O

A	O
total	O
of	O
1434	O
serological	O
metabolites	O
were	O
assessed	O
in	O
early	O
-	O
stage	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
cases	O
(	O
n	O
=	O
41	O
)	O
and	O
asymptomatic	B:C0231221
matched	I:C0231221
controls	I:C0231221
(	O
n	O
=	O
40	O
)	O
.	O

Post	O
-	O
quality	O
control	O
,	O
statistical	O
analysis	O
identified	O
n	O
=	O
20	O
metabolites	B:C0870883
,	O
predominantly	O
metabolites	O
of	O
the	O
fatty	O
acid	O
oxidation	O
pathway	O
,	O
associated	O
with	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
and	O
mild	O
cognitive	I:C1270972
impairment	I:C1270972
.	O

Post	O
-	O
quality	O
control	O
,	O
statistical	O
analysis	O
identified	O
n	O
=	O
20	O
metabolites	O
,	O
predominantly	O
metabolites	B:C0870883
of	O
the	O
fatty	O
acid	O
oxidation	O
pathway	O
,	O
associated	O
with	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
and	O
mild	O
cognitive	I:C1270972
impairment	I:C1270972
.	O

Post	O
-	O
quality	O
control	O
,	O
statistical	O
analysis	O
identified	O
n	O
=	O
20	O
metabolites	O
,	O
predominantly	O
metabolites	O
of	O
the	O
fatty	O
acid	O
oxidation	O
pathway	O
,	O
associated	O
with	O
Parkinson	B:C0030567
's	I:C0030567
disease	I:C0030567
and	O
mild	O
cognitive	I:C1270972
impairment	I:C1270972
.	O

Post	O
-	O
quality	O
control	O
,	O
statistical	O
analysis	O
identified	O
n	O
=	O
20	O
metabolites	O
,	O
predominantly	O
metabolites	O
of	O
the	O
fatty	O
acid	O
oxidation	O
pathway	O
,	O
associated	O
with	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
and	O
mild	B:C1270972
cognitive	I:C1270972
impairment	I:C1270972
.	O

Receiver	B:C0450973
operator	I:C0450973
curve	I:C0450973
assessment	I:C0450973
confirmed	O
that	O
the	O
nine	O
fatty	O
acid	I:C1158366
oxidation	I:C1158366
metabolites	O
had	O
good	O
predictive	I:C0589148
accuracy	I:C0589148
(	O
area	O
under	O
curve	O
=	O
0.857	O
)	O
for	O
early	O
-	O
stage	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
and	O
mild	O
cognitive	I:C1270972
impairment	I:C1270972
(	O
area	O
under	O
curve	O
=	O
0.759	O
)	O
.	O

Receiver	O
operator	I:C0450973
curve	I:C0450973
assessment	I:C0450973
confirmed	O
that	O
the	O
nine	O
fatty	B:C1158366
acid	I:C1158366
oxidation	I:C1158366
metabolites	O
had	O
good	O
predictive	I:C0589148
accuracy	I:C0589148
(	O
area	O
under	O
curve	O
=	O
0.857	O
)	O
for	O
early	O
-	O
stage	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
and	O
mild	O
cognitive	I:C1270972
impairment	I:C1270972
(	O
area	O
under	O
curve	O
=	O
0.759	O
)	O
.	O

Receiver	O
operator	I:C0450973
curve	I:C0450973
assessment	I:C0450973
confirmed	O
that	O
the	O
nine	O
fatty	O
acid	I:C1158366
oxidation	I:C1158366
metabolites	B:C0870883
had	O
good	O
predictive	I:C0589148
accuracy	I:C0589148
(	O
area	O
under	O
curve	O
=	O
0.857	O
)	O
for	O
early	O
-	O
stage	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
and	O
mild	O
cognitive	I:C1270972
impairment	I:C1270972
(	O
area	O
under	O
curve	O
=	O
0.759	O
)	O
.	O

Receiver	O
operator	I:C0450973
curve	I:C0450973
assessment	I:C0450973
confirmed	O
that	O
the	O
nine	O
fatty	O
acid	I:C1158366
oxidation	I:C1158366
metabolites	O
had	O
good	B:C0589148
predictive	I:C0589148
accuracy	I:C0589148
(	O
area	O
under	O
curve	O
=	O
0.857	O
)	O
for	O
early	O
-	O
stage	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
and	O
mild	O
cognitive	I:C1270972
impairment	I:C1270972
(	O
area	O
under	O
curve	O
=	O
0.759	O
)	O
.	O

Receiver	O
operator	I:C0450973
curve	I:C0450973
assessment	I:C0450973
confirmed	O
that	O
the	O
nine	O
fatty	O
acid	I:C1158366
oxidation	I:C1158366
metabolites	O
had	O
good	O
predictive	I:C0589148
accuracy	I:C0589148
(	O
area	O
under	O
curve	O
=	O
0.857	O
)	O
for	O
early	O
-	O
stage	O
Parkinson	B:C0030567
's	I:C0030567
disease	I:C0030567
and	O
mild	O
cognitive	I:C1270972
impairment	I:C1270972
(	O
area	O
under	O
curve	O
=	O
0.759	O
)	O
.	O

Receiver	O
operator	I:C0450973
curve	I:C0450973
assessment	I:C0450973
confirmed	O
that	O
the	O
nine	O
fatty	O
acid	I:C1158366
oxidation	I:C1158366
metabolites	O
had	O
good	O
predictive	I:C0589148
accuracy	I:C0589148
(	O
area	O
under	O
curve	O
=	O
0.857	O
)	O
for	O
early	O
-	O
stage	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
and	O
mild	B:C1270972
cognitive	I:C1270972
impairment	I:C1270972
(	O
area	O
under	O
curve	O
=	O
0.759	O
)	O
.	O

Our	O
study	O
indicates	O
that	O
fatty	B:C1158366
acid	I:C1158366
oxidation	I:C1158366
may	O
be	O
an	O
important	O
component	O
in	O
the	O
pathophysiology	O
of	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
and	O
may	O
have	O
potential	O
as	O
a	O
diagnostic	O
biomarker	I:C1880302
for	O
disease	O
onset	O
and	O
mild	O
cognitive	I:C1270972
impairment	I:C1270972
.	O

Our	O
study	O
indicates	O
that	O
fatty	O
acid	I:C1158366
oxidation	I:C1158366
may	O
be	O
an	O
important	O
component	O
in	O
the	O
pathophysiology	O
of	O
Parkinson	B:C0030567
's	I:C0030567
disease	I:C0030567
and	O
may	O
have	O
potential	O
as	O
a	O
diagnostic	O
biomarker	I:C1880302
for	O
disease	O
onset	O
and	O
mild	O
cognitive	I:C1270972
impairment	I:C1270972
.	O

Our	O
study	O
indicates	O
that	O
fatty	O
acid	I:C1158366
oxidation	I:C1158366
may	O
be	O
an	O
important	O
component	O
in	O
the	O
pathophysiology	O
of	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
and	O
may	O
have	O
potential	O
as	O
a	O
diagnostic	B:C1880302
biomarker	I:C1880302
for	O
disease	O
onset	O
and	O
mild	O
cognitive	I:C1270972
impairment	I:C1270972
.	O

Our	O
study	O
indicates	O
that	O
fatty	O
acid	I:C1158366
oxidation	I:C1158366
may	O
be	O
an	O
important	O
component	O
in	O
the	O
pathophysiology	O
of	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
and	O
may	O
have	O
potential	O
as	O
a	O
diagnostic	O
biomarker	I:C1880302
for	O
disease	O
onset	O
and	O
mild	B:C1270972
cognitive	I:C1270972
impairment	I:C1270972
.	O

